SOLARIS VACCINES, INC.

FORT COLLINS, CO · Founded 2021 · Biotech · Private

SolaVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis vaccine created using riboflavin photosensitizer and UV light inactivation

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · solarisvaccines.com

Sector: Biotech
Headquarters: FORT COLLINS, CO
Founded: 2021
Latest Form D: $110K, May 2023
Total capital: $4.3M

Federal grants: $2.1M; 4 awards · 2023–2025; Rank in peer group#453 of 514
Private capital raised: $610K; 2 Form D · last May 2023; 41 months since last filing
Federal contracts: $1.5M; 2 awards · Defense; Rank in Biotech#155 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Jul 2025Federal grantHealth and Human S · Phase I · A whole-cell inactivated vaccine for improved protection against tuberculosis$270K
Jul 2025Federal contractDefense · Dha Phase II SBIR Contract For Vacciraptor: High-throughput, Continuous Flow-through System For Psoralen-uva Inactivation$1.3M
Jul 2025Federal grantDefense · Phase II · Dha Phase II SBIR Contract For Vacciraptor: High-throughput, Continuous Flow-through System For Psoralen-uva Inactivation$1.3M
Jun 2024Federal contractDefense · Dha SBIR Phase I Vacciraptor: High-throughput, Continuous Flow-through Device For Psoralen-uva Inactivation Of Dengue Virus$250K
Jun 2024Federal grantDefense · Phase I · Dha SBIR Phase I Vacciraptor: High-throughput, Continuous Flow-through Device For Psoralen-uva Inactivation Of Dengue Virus$250K
May 2023Private capital raisedForm D · SEC · 2nd filing$110K
Apr 2023Federal grantHealth and Human S · Phase I · Flu Vaccine Production Using a Novel Pandemic Response and Prevention Manufacturing Method$299K
Jan 2022Private capital raisedForm D · SEC · 1st filing$500K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Michael Calvin ArtingerResearcherExecutive Officer, DirectorLinked by $569K in grants as PI
Robert Calvin GoforthDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

INAEDIS, INCSimilar federal contract value in Biotech · $1.6M in contracts
ICAGEN, INC.Similar federal contract value in Biotech · $1.6M in contracts
PRESSURE BIOSCIENCES, INC.Similar federal contract value in Biotech · $1.6M in contracts
Arytha Biosciences, LLCSimilar federal contract value in Biotech · $1.5M in contracts
FIREBIRD BIOMOLECULAR SCIENCES LLCSimilar federal contract value in Biotech · $1.4M in contracts
Cofactor Genomics, Inc.Similar federal contract value in Biotech · $1.4M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.